Updated on 2025/06/23

Information

 

写真a

 
TSUDA YASUO
 
Organization
Faculty of Medical Sciences Department of Clinical Medicine Assistant Professor
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
Tel
092-642-5466
Profile
Treatment of gastroenterological surgery and research of cancer.
External link

Research Areas

  • Life Science / Digestive surgery

Degree

  • Ph D （ 2018.3 Kyushu University ）

Research History

  • Kyushu University 消化器・総合外科 Assistant Professor 

    2025.4 - Present

  • Kyushu University 外科 Assistant Professor 

    2023.4 - 2025.3

  • 国立病院機構　九州医療センター 消化管外科 医員 

    国立病院機構　九州医療センター

    2020.4 - 2023.3

  • Kyushu University 消化器・総合外科 医員 

    2018.4 - 2020.3

  • 公益財団法人がん研究会　有明病院 胃外科 医員 

    公益財団法人がん研究会　有明病院

    2016.4 - 2018.3

  • 麻生飯塚病院 外科 医長代理 

    麻生飯塚病院

    2015.4 - 2016.3

  • Kyushu University 消化器・総合外科 大学院 

    2011.4 - 2015.3

  • 国立病院機構　九州医療センター  臨床研修医 

    国立病院機構　九州医療センター

    2009.4 - 2011.3

  • ２００９年４月-2011年３月　国立病院機構　九州医療センター　臨床研修医 2011年4月-2015年3月　九州大学病院　消化器総合外科　医員 2015年4月-２０１６年３月　株式会社　麻生飯塚病院　外科　医長代理 2016年4月-2018年3月　がん研究会有明病院　胃外科　医員 2018年4月-2020年3月　九州大学病院　消化器総合外科　医員 2020年4月-2023年3月　国立病院機構　九州医療センター　医員   

    ２００９年４月-2011年３月　国立病院機構　九州医療センター　臨床研修医 2011年4月-2015年3月　九州大学病院　消化器総合外科　医員 2015年4月-２０１６年３月　株式会社　麻生飯塚病院　外科　医長代理 2016年4月-2018年3月　がん研究会有明病院　胃外科　医員 2018年4月-2020年3月　九州大学病院　消化器総合外科　医員 2020年4月-2023年3月　国立病院機構　九州医療センター　医員

▼display all

Education

  • Kyushu University   医学研究院   消化器・総合外科

    2011.4 - 2015.3

  • Hiroshima University   医学部   医学科

    2003.4 - 2009.3

Research Interests・Research Keywords

  • Research theme： Preserving right bronchial artery attaching azygos vein arch procedure in esophagectomy for esophageal cancer.

    Keyword： 食道癌、右気管支動脈

    Research period： 2025.4 - Present

  • Research theme： Laparoscopic endoscopic co-operative surgery preserved the EGJ for GIST.

    Keyword： GIST, LECS

    Research period： 2025.4 - Present

  • Research theme： Esophageal cancer

    Keyword： 食道癌、シングルセル

    Research period： 2024.4 - 2026.3

  • Research theme： Development of liquid biopsy for the gastroenterological cancer.

    Keyword： Liquid biopsy

    Research period： 2024.4 - 2024.12

Awards

  • 令和５年度別府市医師会学術集会　若手臨床医賞

    2023.2   別府市医師会学術集会   大腸がん術後補助化学療法の有効性を評価する実装的な方法の開発

Papers

  • ASO Visual Abstract: Clinical and Biological Significance of Sodium Channel Modifier 1 as a Component of the Minor Spliceosome in Hepatocellular Carcinoma

    Ofuchi, T; Otsu, H; Hosoda, K; Ikehara, T; Higuchi, S; Tatsumi, T; Omachi, K; Tsujimoto, A; Hirose, K; Tsuda, Y; Yonemura, Y; Hayashi, H; Masuda, T; Iwatsuki, M; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   32 ( 6 )   4530 - 4531   2025.6   （ ISSN:1068-9265 eISSN:1534-4681 ）

    　More details

    Publisher：Annals of Surgical Oncology  

    DOI： 10.1245/s10434-025-17242-8

    Web of Science

    Scopus

    PubMed

  • Clinical and Biological Significance of Sodium Channel Modifier 1 as a Component of the Minor Spliceosome in Hepatocellular Carcinoma

    Ofuchi, T; Otsu, H; Hosoda, K; Ikehara, T; Higuchi, S; Tatsumi, T; Omachi, K; Tsujimoto, A; Hirose, K; Tsuda, Y; Yonemura, Y; Hayashi, H; Masuda, T; Iwatsuki, M; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   32 ( 6 )   4508 - 4519   2025.6   （ ISSN:1068-9265 eISSN:1534-4681 ）

    　More details

    Language：English   Publisher：Annals of Surgical Oncology  

    Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide. The progression of HCC involves complex molecular mechanisms, including chromosomal amplification and alterations in pre-mRNA splicing. In this study, we investigated sodium channel modifier 1 (SCNM1), a component of the minor spliceosome, as a potential oncogenic driver of HCC. Methods: We analyzed SCNM1 expression and its relationship with clinical outcomes using The Cancer Genome Atlas and GSE14520 datasets and patient samples. Functional assays, including realtime-quantitative polymerase chain reaction, Western blotting, colony formation, and apoptosis analyses, were performed to elucidate the role of SCNM1 in HCC progression. We also evaluated the correlations between SCNM1 and its downstream targets DERL2 and BAG6. Results: Because of DNA copy number gain and arm-level amplification of chromosome 1q, SCNM1 expression was significantly elevated in HCC tissues. High SCNM1 expression correlated with poor prognosis and was identified as an independent prognostic factor. Via its splicing activity, SCNM1 promotes tumor growth, suppresses apoptosis, and regulates the expressions of DERL2 and BAG6, which contribute to cancer cell survival by facilitating protein degradation and suppressing apoptosis. Overexpression of SCNM1 is observed in multiple cancer types, suggesting a broad oncogenic role. Conclusions: Sodium channel modifier 1 plays a critical role in HCC progression by regulating the key pathways involved in tumor proliferation and survival. Its restricted expression in specific cancer types and influence on the minor spliceosome highlights its potential as a cancer-specific therapeutic target. Further research on SCNM1-targeted therapies may provide innovative strategies for treating HCC and other cancers.

    DOI： 10.1245/s10434-025-17108-z

    Web of Science

    Scopus

    PubMed

  • <i>SEC61G</i> promotes colorectal cancer progression by regulating cytosolic Ca<SUP>2+</SUP> concentration

    Higuchi, S; Otsu, H; Masuda, T; Hashimoto, M; Nakano, Y; Hosoda, K; Hirose, K; Ikehara, T; Ofuchi, T; Tsuda, Y; Yonemura, Y; Uemura, M; Eguchi, H; Doki, Y; Mimori, K

    JOURNAL OF GASTROENTEROLOGY   2025.5   （ ISSN:0944-1174 eISSN:1435-5922 ）

    　More details

    Language：English   Publisher：Journal of Gastroenterology  

    Background: Intracellular calcium (Ca<sup>2+</sup>) signaling regulates key cancer processes. Research findings suggest that the SEC61 complex, involved in protein translocation, contributes to calcium leakage from the endoplasmic reticulum. However, the mechanism by which SEC61 Translocon Subunit Gamma (SEC61G), a component of this complex, influences colorectal cancer (CRC) progression remains unclear. Methods: Bioinformatics analysis was performed using The Cancer Genome Atlas data sets to identify candidate genes on chromosome 7p, examine their association with DNA copy number amplification. In addition, SEC61G expression in CRC cells and tissues was validated using reverse-transcription quantitative polymerase chain reaction and immunohistochemistry. Moreover, in vitro and in vivo experiments were performed to investigate the effects of SEC61G overexpression and knockdown on CRC cell proliferation. Furthermore, publicly available single-cell RNA sequencing (scRNA-seq) and spatial transcriptome sequencing (ST-seq) data were used to validate the role of SEC61G in CRC. Results: SEC61G was significantly upregulated in CRC tissues and was correlated with poor prognosis in patients with CRC. SEC61G overexpression enhanced cell proliferation and activated the EGFR pathway, promoting cell cycle progression from the G1 to S phase. In addition, SEC61G overexpression increased cytosolic Ca<sup>2+</sup> levels, which activated EGFR signaling via calmodulin. Moreover, analyses of scRNA-seq and ST-seq data confirmed that SEC61G expression was higher in tumor epithelial cells and that it was co-expressed with EGFR pathway-related genes. Conclusions: SEC61G promotes CRC progression by regulating cytosolic Ca<sup>2+</sup> concentration, EGFR activation, and cell cycle progression, highlighting its potential as a prognostic biomarker and therapeutic target in CRC.

    DOI： 10.1007/s00535-025-02259-3

    Web of Science

    Scopus

    PubMed

  • Laparoscopically resected appendiceal dual tumor composed of goblet cell carcinoma and low-grade mucinous neoplasm: a case report and literature review

    Hirose, K; Minami, K; Oshiro, Y; Taniguchi, D; Kajiwara, Y; Tsuda, Y; Otsu, H; Yonemura, Y; Mimori, K

    INTERNATIONAL CANCER CONFERENCE JOURNAL   14 ( 2 )   136 - 142   2025.4   （ ISSN:2192-3183 ）

    　More details

  • Programmed Cell Death 10<i> (PDCD10</i>) Is a Candidate Tumor-associated Gene in Esophageal Squamous Cell Carcinoma

    Hiraki, Y; Masuda, T; Motomura, Y; Tobo, T; Saito, H; Hirose, K; Ofuchi, T; Tsuda, Y; Otsu, H; Yonemura, Y; Kai, S; Hirakawa, M; Ishigami, K; Mimori, K

    ANTICANCER RESEARCH   45 ( 4 )   1419 - 1433   2025.4   （ ISSN:0250-7005 eISSN:1791-7530 ）

    　More details

    Language：English   Publisher：Anticancer Research  

    Background/Aim: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor survival rates. Effective molecular-targeted therapies are urgently needed. This study aimed to identify novel candidate tumor-associated genes in ESCC by analyzing chromosomal amplification regions. Materials and Methods: DNA copy number variation (CNV) and mRNA expression data were obtained from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE). Single-cell RNA sequencing data from Gene Expression Omnibus (GEO) were analyzed using Scanpy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) ESCC tissues. PDCD10 was identified as a potential tumor-associated gene, and its association with clinicopathological factors and prognostic impact was evaluated using Kaplan-Meier survival and Cox regression analyses. Pathway analysis was performed to investigate the biological processes, and drug sensitivity profiling was conducted to identify compounds whose efficacy correlated with PDCD10 expression in ESCC cell lines. Results: PDCD10, a signaling protein involved in cell proliferation and vascular development, showed significant amplification and over-expression in ESCC cases. High PDCD10 expression was associated with poor prognosis. Single-cell RNA sequencing confirmed its tumor-specific expression. GSEA revealed enrichment of mTORC1 signaling, E2F, and Myc target pathways in high PDCD10-expressing tumors. Drug sensitivity analysis identified Azelaic acid and Rebamipide as compounds whose efficacy correlated with PDCD10 expression in ESCC cell lines. Conclusion: PDCD10 could be a novel tumor-associated gene associated with tumor progression and poor prognosis in ESCC. Azelaic acid and Rebamipide are candidate therapeutic agents targeting PDCD10.

    DOI： 10.21873/anticanres.17527

    Web of Science

    Scopus

    PubMed

  • Laparoscopically resected appendiceal dual tumor composed of goblet cell carcinoma and low-grade mucinous neoplasm: a case report and literature review(タイトル和訳中)

    Hirose Kosuke, Minami Kazuhito, Oshiro Yumi, Taniguchi Daisuke, Kajiwara Yuichiro, Tsuda Yasuo, Otsu Hajime, Yonemura Yusuke, Mimori Koshi

    International Cancer Conference Journal   14 ( 2 )   136 - 142   2025.4

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Mechanisms of hepatocellular carcinoma recurrence after liver transplantation in the immunosuppressed state

    Ikehara, T; Onishi, M; Hosoda, K; Motomoura, Y; Ando, Y; Hirose, K; Dairaku, K; Hiraki, Y; Tsuda, Y; Nagao, Y; Yonemura, Y; Masuda, T; Toshima, T; Yoshizumi, T; Soejima, Y; Mimori, K

    CANCER SCIENCE   116   388 - 388   2025.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Propagermanium treatment increased CD8 positive T cell in breast cancer

    Ando, Y; Masuda, T; Yoshiga, R; Kawata, K; Hirose, K; Ikehara, T; Tatsumi, T; Matsumoto, C; Shibuta, S; Ono, Y; Hosoda, K; Dairaku, K; Tsuda, Y; Ohtsu, H; Yonemura, Y; Mimori, K

    CANCER SCIENCE   116   349 - 349   2025.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Polarity gene PARD6B promotes tumor growth via MYC expression in colorectal cancer

    Hirose, K; Masuda, T; Matsumoto, C; Ikehara, T; Tatsumi, T; Hosoda, K; Ando, Y; Tsuda, Y; Otsu, H; Yonemura, Y; Mimori, K

    CANCER SCIENCE   116   730 - 730   2025.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer

    Nakano, T; Takao, S; Dairaku, K; Uno, N; Low, SK; Hashimoto, M; Tsuda, Y; Hisamatsu, Y; Toshima, T; Yonemura, Y; Masuda, T; Eto, K; Ikegami, T; Fukunaga, Y; Niida, A; Nagayama, S; Mimori, K

    CANCER SCIENCE   115 ( 6 )   1989 - 2001   2024.6   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

    Language：English   Publisher：Cancer Science  

    Considering the cost and invasiveness of monitoring postoperative minimal residual disease (MRD) of colorectal cancer (CRC) after adjuvant chemoradiotherapy (ACT), we developed a favorable approach based on methylated circulating tumor DNA to detect MRD after radical resection. Analyzing the public database, we identified the methylated promoter regions of the genes FGD5, GPC6, and MSC. Using digital polymerase chain reaction (dPCR), we termed the “amplicon of methylated sites using a specific enzyme” assay as “AMUSE.” We examined 180 and 114 pre- and postoperative serial plasma samples from 28 recurrent and 19 recurrence-free pathological stage III CRC patients, respectively. The results showed 22 AMUSE-positive of 28 recurrent patients (sensitivity, 78.6%) and 17 AMUSE-negative of 19 recurrence-free patients (specificity, 89.5%). AMUSE predicted recurrence 208 days before conventional diagnosis using radiological imaging. Regarding ACT evaluation by the reactive response, 19 AMUSE-positive patients during their second or third blood samples showed a significantly poorer prognosis than the other patients (p = 9E-04). The AMUSE assay stratified four groups by the altered patterns of tumor burden postoperatively. Interestingly, only 34.8% of cases tested AMUSE-negative during ACT treatment, indicating eligibility for ACT. The AMUSE assay addresses the clinical need for accurate MRD monitoring with universal applicability, minimal invasiveness, and cost-effectiveness, thereby enabling the timely detection of recurrences. This assay can effectively evaluate the efficacy of ACT in patients with stage III CRC following curative resection. Our study strongly recommends reevaluating the clinical application of ACT using the AMUSE assay.

    DOI： 10.1111/cas.16149

    Web of Science

    Scopus

    PubMed

  • 大腸癌の根治療法後の最小残存病変をモニタリングするための実施可能なアッセイ法(Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer)

    Nakano Takafumi, Takao Seiichiro, Dairaku Katsushi, Uno Naoki, Low Siew-Kee Amanda, Hashimoto Masahiro, Tsuda Yasuo, Hisamatsu Yuichi, Toshima Takeo, Yonemura Yusuke, Masuda Takaaki, Eto Ken, Ikegami Toru, Fukunaga Yosuke, Niida Atsushi, Nagayama Satoshi, Mimori Koshi

    Cancer Science   115 ( 6 )   1989 - 2001   2024.6   （ ISSN:1347-9032 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

    血漿中の微量な循環腫瘍DNA(ctDNA)のメチル化を検出することによりステージIIIの大腸癌患者の術後の微小残存病変(MRD)をモニターできるか評価した。公開データベースを解析し、FGD5、GPC6、MSC遺伝子のメチル化されたプロモーター領域を同定した。デジタルPCRを用いた特異的酵素を用いたメチル化部位のアンプリコンアッセイを「AMUSE」と名付けた。病理学的ステージIIIの大腸癌再発患者28例および無再発患者19例それぞれの術前術後の連続血漿検体、180検体および114検体を調べた。その結果、再発患者28例中22例がAMUSE陽性(感度78.6%)、無再発患者19例中17例がAMUSE陰性(特異度89.5%)であった。AMUSEはX線画像診断による従来の診断より208日早く再発を予測した。反応性応答による術後補助化学放射線療法(ACT)評価に関しては、2回目または3回目の採血でAMUSE陽性の患者19例は、他の患者より有意に予後不良であった。AMUSEアッセイにより、術後の腫瘍負荷の変化パターンによって4群に層別化された。以上より、AMUSEアッセイは、正確なMRDモニタリングに対する臨床的ニーズに対応し、普遍的な適用性、最小限の侵襲性、費用対効果により、タイムリーな再発の発見を可能にすることが示唆された。

  • mplementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer. Reviewed International journal

    Nakano T, Takao S, Dairaku K, Uno N, Low SA, Hashimoto M, Tsuda Y, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Eto K, Ikegami T, Fukunaga Y, Niida A, Nagayama S, Mimori K.

    Cancer Sci.   2024.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.16149.

  • Clinical significance and functional analysis of a novel driver gene SETBP1 in breast cancer

    Ando, Y; Masuda, T; Hayashi, N; Shibuta, S; Ono, Y; Ikehara, T; Tatsumi, T; Matsumoto, C; Dairaku, K; Hosoda, K; Abe, T; Hirose, K; Tsuda, Y; Nagao, Y; Yonemura, Y; Mimori, K

    CANCER SCIENCE   115   1604 - 1604   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Tumor necrosis factor superfamily member 4 is a candidate driver gene for hepatocellular carcinoma

    Hosoda, K; Masuda, T; Saito, H; Motomura, Y; Ando, Y; Abe, T; Dairaku, K; Nakano, Y; Hiraki, Y; Ikehara, T; Yonemura, Y; Nagao, Y; Tsuda, Y; Hirose, K; Soejima, Y; Mimori, K

    CANCER SCIENCE   115   1281 - 1281   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Proteasome 26S Subunit, Non-ATPase 12(PSMD12) on chromosome 17 is a candidate driver gene of lung adenocarcinoma (LUAD)

    Ono, Y; Masuda, T; Shibuta, S; Hirose, K; Matsumoto, C; Miyata, Y; Hosoda, K; Dairaku, K; Nakano, Y; Abe, T; Tsuda, Y; Nagao, Y; Yonemura, Y; Takenaka, T; Yoshizumi, T; Mimori, K

    CANCER SCIENCE   115   1290 - 1290   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Identification of KBTBD2, a candidate driver gene of gastric cancer, and its clinical significance

    Kawata, K; Tatsumi, T; Masuda, T; Ando, Y; Hirose, K; Tsuda, Y; Nagao, Y; Yonemura, Y; Yoshizumi, T; Mimori, K

    CANCER SCIENCE   115   923 - 923   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Identification of IMPAD1, a candidate driver gene of gastric cancer, and its clinical significance.

    Tatsumi, T; Masuda, T; Matsumoto, C; Ono, Y; Shibuta, S; Hosoda, K; Nakano, Y; Dairaku, K; Abe, T; Ando, Y; Hirose, K; Tsuda, Y; Nagao, Y; Yonemura, Y; Sho, M; Mimori, K

    CANCER SCIENCE   115   584 - 584   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Identification of candidate driver gene PDCD10 and selection of therapeutic drug candidates in ESCC

    Hiraki, Y; Masuda, T; Motomura, Y; Dairaku, K; Abe, T; Ando, Y; Nakano, Y; Hosoda, K; Tatsumi, T; Kai, S; Tsuda, Y; Nagao, Y; Yonemura, Y; Hirakawa, M; Mimori, K

    CANCER SCIENCE   115   1291 - 1291   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Detection of PARD6B gene as a candidate of driver gene in colorectal cancer

    Hirose, K; Masuda, T; Ono, Y; Shibuta, S; Ando, Y; Tsuda, Y; Nagao, Y; Yonemura, Y; Mimori, K

    CANCER SCIENCE   115   1280 - 1280   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Clinical significance of ZNF707, a novel driver gene candidate for colorectal cancer

    Higuchi, S; Masuda, T; Tsuda, Y; Nagao, Y; Yonemura, Y; Uemura, M; Eguchi, H; Doki, Y; Mimori, K

    CANCER SCIENCE   115   1288 - 1288   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Clinical significance of SLC12A9, a novel candidate driver gene for colorectal cancer

    Dairaku, K; Masuda, T; Hosoda, K; Hiraki, Y; Nakano, Y; Abe, T; Ando, Y; Motomura, Y; Hirose, K; Yoshiga, R; Tsuda, Y; Nagao, Y; Yonemura, Y; Ikegami, T; Eto, K; Mimori, K

    CANCER SCIENCE   115   612 - 612   2024.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Prognostic significance of a novel index score based on the inflammation-based prognostic scores of patients with colorectal cancer Reviewed International journal

    Kudou K, Hasuda H, Tsuda Y, Kusumoto E, Uehara H, Yoshida R, Koga T, Yamashita YI, Sakaguchi Y, Kusumoto T.

    J Gastroenterol Hepatol.   38 ( 10 )   1750 - 1759.   2023.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/jgh.16223.

  • Prognostic significance of a novel index score based on the inflammation-based prognostic scores of patients with colorectal cancer

    Kudou K., Hasuda H., Tsuda Y., Kusumoto E., Uehara H., Yoshida R., Koga T., Yamashita Y.I., Sakaguchi Y., Kusumoto T.

    Journal of Gastroenterology and Hepatology Australia   38 ( 10 )   1750 - 1759   2023.10   （ ISSN:08159319 ）

    　More details

    Publisher：Journal of Gastroenterology and Hepatology Australia  

    Background and Aim: This study aimed to clarify the prognostic value of various inflammation-based prognostic scores (IBPSs) in patients who underwent radical surgery for colorectal cancer (CRC) and to develop a novel prognostic index using IBPSs and other predictive factors. Methods: Data of 1157 patients who underwent radical surgery for CRC were reviewed. The predictive value of various IBPSs in determining the CRC prognosis was compared. A novel index score based on the IBPSs and other parameters that were associated with survival in patients with CRC was established, and its usefulness was evaluated. Results: The patients were randomly divided into the training (n = 694) and validation (n = 463) sets. Male sex (P = 0.0001), age ≥ 75 years (P < 0.0001), a carcinoembryonic antigen (CEA) level of > 5 (P = 0.0009), a C-reactive protein/albumin ratio (CAR) of ≥ 0.04 (P = 0.0033), and a prognostic nutritional index (PNI) of < 43.1 (P = 0.0004) were poor independent prognostic factors of overall survival. The novel index score was calculated based on the scores of these five prognostic factors. The Kaplan–Meier survival curves showed that the CRC patients with higher novel index scores in the training and validation datasets had poorer overall survival. Conclusions: CAR and PNI were superior to other IBPSs for predicting the prognosis of CRC patients. The novel index score established based on sex, age, CEA level, CAR, and PNI can predict the prognosis of CRC with more precise and clearer stratification than the individual parameters alone.

    DOI： 10.1111/jgh.16223

    Scopus

  • Comparison of Laparoscopic and Open Emergency Surgery for Colorectal Perforation: A Retrospective Study

    Kudou K., Kusumoto T., Hasuda H., Tsuda Y., Kusumoto E., Uehara H., Yoshida R., Sakaguchi Y.

    Journal of Laparoendoscopic and Advanced Surgical Techniques   33 ( 5 )   464 - 470   2023.5   （ ISSN:10926429 ）

    　More details

    Publisher：Journal of Laparoendoscopic and Advanced Surgical Techniques  

    Background: This study aimed to clarify the safety and efficacy of laparoscopic surgery for colorectal perforation by comparing the clinical outcomes between laparoscopic and open emergency surgery for colorectal perforation. Materials and Methods: We retrospectively reviewed the data of 116 patients who underwent surgery for colorectal perforation. The patients were categorized into two groups: the open group included patients who underwent laparotomy, and the laparoscopic group included those who underwent laparoscopic surgery. Clinical and operative characteristics and postoperative outcomes were evaluated. Results: The open and laparoscopic groups included 67 and 49 patients, respectively. More than half of the patients in both groups developed perforation in the sigmoid colon (open, 58.2%; laparoscopic, 61.2%). The most common cause of perforation was diverticulum, followed by colorectal cancer. The mean intraoperative blood loss was significantly lower in the laparoscopic group than in the open group (70.0 mL versus 160.3 mL; P = .0290). The incidence of surgical site infection was lower in the laparoscopic group than in the open group (2.0% versus 13.4%; P = .0430). There were no significant differences in either the short- or long-term outcomes between the two groups. Univariate and multivariate analyses showed that the choice of surgical approach (open versus laparoscopic) did not affect overall survival in patients with colorectal perforation. Conclusion: The laparoscopic approach for colorectal perforation in an emergency setting can be safely performed and provides certain advantages over an open approach in suitable patients.

    DOI： 10.1089/lap.2022.0423

    Scopus

  • Comparison of Laparoscopic and Open Emergency Surgery for Colorectal Perforation: A Retrospective Study. Reviewed International journal

    Kudou K, Kusumoto T, Hasuda H, Tsuda Y, Kusumoto E, Uehara H, Yoshida R, Sakaguchi Y.

    J Laparoendosc Adv Surg Tech A.   33 ( 5 )   464 - 470   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1089/lap.2022.0423.

  • 手術とニボルマブによる術後補助療法後に再発がなかった食道原発悪性黒色腫(Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab)

    Nambara Sho, Sakaguchi Yoshihisa, Tsuda Yasuo, Kudou Kensuke, Kusumoto Eiji, Yoshida Rintaro, Kusumoto Tetsuya, Ikejiri Koji

    International Cancer Conference Journal   12 ( 2 )   100 - 103   2023.4

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    症例は60歳女性で、嚥下障害を主訴に当院を受診した。皮膚筋炎と乳癌の既往があった。食道内視鏡検査では、下部胸部食道に黒色色素沈着を伴う60mm大の暗褐色隆起性腫瘍を認めた。生検標本の病理組織学的検査では、楕円形の過色素性核、時折明瞭な核小体、境界の不鮮明な細胞質、メラニン色素を有する異型円形細胞を認めた。免疫組織化学染色ではヒトメラノーマブラック45とメラニンAが陽性であった。T3N0M0ステージII食道原発悪性黒色腫と診断した。根治的食道切除術を施行し、術後治療としてニボルマブ(240mg/body)を2週間毎に投与した。2コース後に両側性気胸が発生したが、胸腔ドレナージにより回復した。ニボルマブ治療を術後1年以上経過した時点でも継続し、再発なく生存した。

  • Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab Reviewed International journal

    Nambara S, Sakaguchi Y, Tsuda Y, Kudou K, Kusumoto E, Yoshida R, Kusumoto T, Ikejiri K.

    Int Cancer Conf J.   12 ( 2 )   100 - 103   2022.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s13691-022-00582-7.

  • 多発癌に対する手術と化学放射線療法後に生じた未分化型食道多形性肉腫の1例(A case of undifferentiated pleomorphic sarcoma in esophagus after multiple cancer treatments of surgery and chemoradiotherapy)

    Ebata Yuho, Sakaguchi Yoshihisa, Tsuda Yasuo, Nambara Sho, Kudou Kensuke, Kusumoto Eiji, Yoshida Rintaro, Kusumoto Tetsuya, Ikejiri Koji

    Surgical Case Reports   8   1 of 7 - 7 of 7   2022.11

    　More details

    Language：English   Publisher：(一社)日本外科学会  

    症例は73歳男性で、内視鏡検査で食道腫瘍を指摘され精査加療目的に当院紹介となった。29年前に胃癌に対する幽門側胃切除、12年前に結腸癌に対する横行結腸切除、11年前に残胃癌に対する内視鏡下粘膜下層剥離術(ESD)を受けていた。10年前に上部胸部食道癌に対するESD、7年前に喉頭・下咽頭癌に対する内視鏡下咽喉頭切除、4年前に再発性喉頭癌に対する化学放射線療法、2年前に上部胸部食道癌に対するESD、1年前に下咽頭癌に対する経口的喉頭鏡手術を受けていた。臨床検査では異常所見はみられず、内視鏡検査で歯列弓から40cmの部位に粘膜下腫瘍に類似する表面平滑な円形病変を認め、超音波内視鏡にて第二層に低エコー性病変が検出された。組織診では肉腫を示唆する所見であったが確定診断には至らず、下部食道切除、残胃切除、空腸再建術を行った。横行結腸、残胃、膵および肝の吻合部に強固な癒着が生じていたためこれを剥離し、続いて下部食道切除術、残胃切除、食道空腸吻合術を施行した。術後の組織病理学的検査では粘膜下層に花筵状パターンを呈する多形性紡錘細胞浸潤を認め、免疫組織化学染色の結果と合わせて未分化型多形性肉腫と診断した。重篤な合併症の発症なく1ヵ月後に退院となり、その後1年、局所再発や遠隔転移なく経過している。

  • Association Between Anti-<i>Helicobacter pylori</i> Antibody Seropositive and De Novo Gallstone Formation After Laparoscopic Sleeve Gastrectomy for Japanese Patients with Severe Obesity

    Hashimoto, K; Nagao, Y; Nambara, S; Tsuda, Y; Kudou, K; Kusumoto, E; Sakaguchi, Y; Kusumoto, T; Ikejiri, K

    OBESITY SURGERY   32 ( 10 )   3404 - 3409   2022.10   （ ISSN:0960-8923 eISSN:1708-0428 ）

    　More details

    Language：English   Publisher：Obesity Surgery  

    Purpose: Patients who have undergone bariatric surgery are at risk for gallstone formation. However, the incidence of gallstone formation after bariatric surgery has not been adequately studied in the Japanese population. We aimed to elucidate the incidence and risk factors for gallstone formation after laparoscopic sleeve gastrectomy (LSG) for Japanese patients with severe obesity. Methods: We conducted a retrospective cohort study among patients with severe obesity treated with LSG between April 2017 and June 2020 at two institutions. Patients who had received previous cholecystectomy, had preoperative gallstones, and had received postoperative prophylactic ursodeoxycholic acid were excluded. Body weight, body mass index, and blood data were collected at each follow-up visit before and after the surgery. Follow-up abdominal ultrasonography was performed 6–12 months after surgery, and the incidence of gallstones was calculated. The association between the data and gallstone formation was evaluated. Results: During the study period, we performed LSG for 98 patients. Of these, 61 cases remained by above conditions and were examined using abdominal ultrasonography over 6 months after surgery. The incidence of gallstones was 23.0% and that of symptomatic gallstones was 3.3%. Anti-Helicobacter pylori antibody seropositive and titer were the only factors that showed significant association with de novo gallstone formation after LSG. Conclusions: Anti-Helicobacter pylori antibody seropositive may be associated with de novo gallstone formation after LSG for Japanese patients with severe obesity. Graphical abstract: [Figure not available: see fulltext.]

    DOI： 10.1007/s11695-022-06253-z

    Web of Science

    Scopus

    PubMed

  • Prediction of hospital mortality after colorectal perforation surgery from inflammation-based prognostic scores

    Kudou K., Kusumoto T., Ebata Y., Nambara S., Tsuda Y., Kusumoto E., Yoshida R., Sakaguchi Y., Ikejiri K.

    Surgery Open Science   8   40 - 46   2022.4

    　More details

    Publisher：Surgery Open Science  

    Background: Inflammation-based prognostic scores have prognostic value in cancer or cardiovascular disease patients. This study evaluated the prognostic value of inflammation-based prognostic scores in colorectal perforation patients. Methods: Data of 97 patients who underwent surgery for colorectal perforation were reviewed. We calculated various inflammation-based prognostic scores and analyzed the relationship between inflammation-based prognostic score and hospital mortality due to colorectal perforation. Results: Multivariate analyses of hospital mortality revealed neutrophil–lymphocyte ratio (P = .0021), C-reactive protein/albumin ratio (P = .0224), and prognostic nutritional index (P = .0078) as independent predictive factors. The Kaplan–Meier analysis showed that patients who met all of the following parameters avoided hospital death: neutrophil–lymphocyte ratio < 30, prognostic nutritional index ≥ 27.2, age < 75 years, and perforation of the left colon. Conclusion: Neutrophil–lymphocyte ratio, C-reactive protein/albumin ratio, and prognostic nutritional index were superior to other inflammation-based prognostic scores in predicting mortality of colorectal perforation. Neutrophil–lymphocyte ratio, prognostic nutritional index, patient's age, and sidedness of the perforation site may be useful parameters to identify subgroups in which a favorable prognosis can be expected.

    DOI： 10.1016/j.sopen.2022.01.003

    Scopus

  • New index combining multiple inflammation-based prognostic scores for predicting the prognosis of gastric cancer patients

    Kudou K., Kusumoto T., Nambara S., Tsuda Y., Kusumoto E., Yoshida R., Sakaguchi Y., Ikejiri K.

    Jgh Open   6 ( 3 )   171 - 178   2022.3

    　More details

    Publisher：Jgh Open  

    Background and Aim: Several inflammation-based scores have prognostic value for patients diagnosed with various cancers. However, using only a single inflammation-based prognostic score may be unreliable, as the cut-off values and relative usefulness among various inflammation-based prognostic scores vary. We established a new combined index of four inflammation-based prognostic scores, namely the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognostic index, and prognostic nutritional index, and assessed its usefulness to predict the prognosis of gastric cancer. Methods and Results: We reviewed the data of 635 patients who underwent surgical resection for gastric cancer. We calculated the combined index as the total value of each of the four included inflammation-based prognostic scores and analyzed the relationship between the combined index and postoperative prognosis of gastric cancer. The new combined index was represented as a value between 0 and 6 in each patient. The Kaplan–Meier survival curves showed that patients whose combined index was 0 had good long-term outcomes, while the prognosis of patients whose combined index ranged from 4 to 6 was poor. Conclusion: This new combined index was strongly associated with poor prognosis in patients who underwent surgery for gastric cancer. It is inferred that it can predict patient prognosis after surgical resection for gastric cancer with a stronger correlation and clearer stratification than a single inflammation-based prognostic score.

    DOI： 10.1002/jgh3.12723

    Scopus

▼display all

Books

  • 鏡視下上部消化管手術に用いる自動縫合器・吻合器の使用法とコツ. 外科. 2017.

    津田康雄

    2024.5 

    　More details

    Language：Japanese  

Presentations

▼display all

MISC

Professional Memberships

  • 日本外科学会

  • 日本消化器外科学会

  • 日本内視鏡外科学会

  • 日本胃癌学会

  • 日本食道学会

  • 日本臨床外科学会

  • 日本消化器病学会

  • 日本肥満治療学会

  • 日本ロボット外科学会

  • 日本臨床腫瘍学会

  • 日本癌治療学会

▼display all

Research Projects

  • OTSアッセイ導入

    2024.4 - 2024.12

  • 空間的シングルセル解析による食道がん免疫寛容機構の解明とオミクスアプローチ

    Grant number：24K10384  2024 - 2026

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    津田 康雄, 三森 功士

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    本研究においては、食道癌に対するマルチオミクス解析を施行し、蛋白・代謝産物レベルで症例間普遍的な治療標的を同定する。特に本研究では転写レベルに関しては空間的トランスクリプトーム解析(VISIUM; Ozato Y, Mimori K. Cell Rep 2023)とscRNAデータをメタボロームプロファイルに変換する解析パイプラインとを併施して、がん細胞あるいは微小環境の免疫担当細胞由来の治療標的分子を同定する。

    CiNii Research

  • ctDNAメチル化マーカーを用いた健常者からがん患者のスクリーニング

    2024

    　 More details

    Grant type：Donation

Educational Activities

  • 外科専攻医の指導及び大学での講義、実習指導

Class subject

  • 消化器外科

    2025.4 - Present   Full year

  • 消化器外科

    2025.4 - Present   First semester

Visiting, concurrent, or part-time lecturers at other universities, institutions, etc.

  • 2024  国立病院機構　九州医療センター  Classification:Affiliate faculty  Domestic/International Classification:Japan 

Media Coverage

  • 腹腔鏡下幽門即胃切除デルタ吻合 Internet

    エチコン  エチコン  2025.3

  • 遠隔手術指導 Newspaper, magazine

    大分合同新聞  大分合同新聞  2024.11

    　More details

    Author：Other 

  • 胃GISTの低侵襲治療 Newspaper, magazine

    大分合同新聞  大分合同新聞  2024.9

    　More details

    Author：Myself 

  • 胃癌の集学的治療 Newspaper, magazine

    大分合同新聞  2023.7

    　More details

    胃癌の集学的治療

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Gastrointestinal Surgery

Clinician qualification

  • Specialist

    日本ロボット外科学会

  • Certifying physician

    日本がん治療認定医機構

  • Certifying physician

    The Japanese Society of Gastroenterological Surgery

  • Certifying physician

    The Japan Esophageal Society

  • 技術認定医

    The Japan Society for Endoscopic Surgery（JSES）

  • Specialist

    The Japanese Society of Gastroenterological Surgery

  • Specialist

    The Japanese Society of Gastroenterology（JSGE）

  • Specialist

    Japan Surgical Society（JSS）

▼display all

Year of medical license acquisition

  • 2009